Alnylam Pharmaceuticals Inc (ALNY)vsRoyalty Pharma Plc (RPRX)
ALNY
Alnylam Pharmaceuticals Inc
$296.11
-4.32%
HEALTHCARE · Cap: $39.51B
RPRX
Royalty Pharma Plc
$49.47
-1.24%
HEALTHCARE · Cap: $29.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 80% more annual revenue ($4.29B vs $2.38B). RPRX leads profitability with a 32.4% profit margin vs 12.6%. ALNY appears more attractively valued with a PEG of 0.59. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
RPRX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.7%
Fair Value
$2429.90
Current Price
$296.11
$2133.79 discount
Margin of Safety
-11.3%
Fair Value
$39.76
Current Price
$49.47
$9.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 57.7%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 49.7x book value
Moderate valuation
4.8% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.6x leaves little room for execution misses.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ALNY profiles as a growth stock while RPRX is a value play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.39 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
RPRX generates stronger free cash flow (827M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 57/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?